A nine-herb traditional Chinese formula reduced gut graft-vs.-host disease severity and suppressed FGF2/PI3K/Akt signaling in a mouse model, according to a new study combining network pharmacology and ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
FOURLIGHT-1 shows atirmociclib plus fulvestrant improved PFS to 9.4 vs 6.6 months after prior CDK4/6 inhibition in HR+/HER2− ...
Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...
These data lend support for Faeth’s multi-node strategy, with two upcoming readouts: FTH-PIK-201 topline data in second-line advanced endometrial cancer by year-end 2026 and FTH-PIK-101 interim data ...
Combining EP300 degradation with AKT inhibition slowed osteosarcoma growth and prolonged survival in preclinical mouse models ...
A natural compound extracted from a medicinal plant has shown surprising promise against rheumatoid arthritis. In rats, it ...
A 2026 review finds that epigenetic changes sustain PI3K/AKT signaling in hepatocellular carcinoma, while experimental ...
Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...
BridgeBio Oncology's total equity value of $226 million is lower than its liquid assets of $344.1 million as of June 30. See ...
Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer; Poster ...
PI3K signaling and crosstalk with ERα and MAPK pathways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results